ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a safe, ...
BACKGROUND: Preeclampsia affects approximately 1 in 10 pregnancies, leading to severe complications and long-term health ...
ImmunityBio (IBRX) shares gained on Friday after the cancer drug developer announced the successful conclusion of two manufacturing engineering programs designed to validate its Cytokine-Enriched NK ...
The intestinal immune system plays a pivotal role in maintaining mucosal homeostasis, acting as the interface between environmental stimuli, host epithelial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results